|
RE-VANA THERAPEUTICS: A STANDOUT QUBIS SUCCESS STORY
Re-Vana Therapeutics is the latest in a growing list of QUBIS-backed ventures achieving global traction. But for QUBIS, this is more than just a milestone - it’s a flagship example of what the organisation was built to do: back bold ideas early, build strong founding teams, and connect them to global opportunity.
“When Re-Vana was still just a concept, QUBIS was the first to believe - and the first cheque in,” said Brian McCaul, CEO at QUBIS. “We worked shoulder to shoulder with the founders, helped shape the business model, built the early team, and mobilised that crucial first round of investment. That groundwork helped Re-Vana become what it is today - a global player built on Northern Ireland innovation.”
Having recognised Re-Vana’s potential at an early stage, Brian McCaul worked closely with the academic team, Dr Raj Thakur and Professor David Jones, to help shape it’s commercial pathway. Supported by the wider QUBIS team, and with Michael O’Rourke taking on the leadership role, QUBIS provided hands-on input across key areas, including intellectual property, company formation, early governance, and early-stage cash support - ensuring the company was well-positioned for growth.
“The early involvement of Brian McCaul and the wider QUBIS team was critical to our success. Their leadership, investment, and strategic input provided the foundation on which we’ve built a global business.” said Michael O’Rourke CEO of Re-Vana.
Re-Vana now stands as one of Queen’s University Belfast’s flagship spin-outs - demonstrating the impact that academic research, when supported by dedicated commercialisation expertise, can have on the global stage. The success of the company highlights the continued value of the QUBIS model in advancing innovation, driving economic growth, and delivering societal benefit through research-led enterprise.
For more updates on QUBIS-backed ventures and partnerships follow us on LinkedIn